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The present in vitro study set out to determine for the first
time the continuous venovenous hemofiltration (CVVH)
clearance of the novel lipopetide antibiotic, daptomycin,
from human whole blood. Factors influencing daptomy-
cin sieving and membrane adsorption were investigated
in an in vitro setting. A recirculation model was estab-
lished and daptomycin was added to the simulated blood
circuit at different concentrations and in different solvent
systems. The concentration of daptomycin over time in
the modelled blood compartment and in ultrafiltrate was
measured by HPLC. Mean sieving coefficients (SCs) of
daptomycin over time were 1 ± 0.05, 0.3 ± 0.02 and 0.4 ±
0.03 in Ringer lactate, Ringer lactate containing human
albumin and plasma, respectively. The CVVH clearance of
daptomycin from whole blood exceeded the physiologi-
cal clearance in an individual with normal renal function.
Adsorption of daptomycin to synthetic surfaces proved
moderate, resulting in loss of around 20% of the initial
dose at 1 hour after the start of CVVH. Since mean SCs of
daptomycin in protein-containing media were higher
than the free fraction in plasma, our results suggest that
besides protein binding, unknown factors such as intrac-
ellular drug partitioning influence sieving of daptomycin
during hemofiltration. Due to the high in vitro CVVH
clearance of daptomycin we determined from human
whole blood, we recommend monitoring of daptomycin
concentrations in patients undergoing hemofiltration.
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